ClinicalTrials.gg
CompletedNCT03818386NANORAD2Updated Sep 15, 2026

Radiotherapy of Multiple Brain Metastases Using AGuIX®

A Phase 2 interventional study of AGuIX® and Whole Brain Radiation Therapy in Brain Metastases, Adult and Radiotherapy, sponsored by University Hospital, Grenoble. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by University Hospital, Grenoble · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Brain Neoplasms with a site in France — 38 open to participants now, 52 under way, 6 of them phase 3. Brain Neoplasms · France.

Enrollment
50th of 132
106 · median 70
Started
2019
with 10 others
Phase 2
40 of 172
3 open now
Registered
97th of 172
by date
Lead sponsor
4 of 172
University Hospital, Grenoble

Among the 172 studies in Brain Neoplasms with a site in France, this one is the 50th largest by enrollment of the 132 interventional ones that give a count, is one of 11 that started in 2019, is one of 40 in phase 2, and was the 97th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

38 of the 172 studies in Brain Neoplasms with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Brain Neoplasms with a site in France, or all of them as a file.
02

Study summary

This is a Prospective Randomized Open Blinded Endpoint phase II clinical trial. The study will be adaptive: an interim analysis is planned after enrolment of 20 patients in each arm of treatment (WBRT and AGuIX® + WBRT), to select and continue the study with group(s) that present the best response rate to the experimental treatment (AGuIX® + WBRT).

The main endpoint will be evaluated by a blinded endpoint committee.

Read the detailed description

The occurrence of brain metastases is a common event in the history of cancer and negatively affects the life expectancy of patients. Their incidence varies between 15 and 50% according to the histologic types. Surgery, stereotactic radiosurgery, radiotherapy and chemotherapy are the main treatments currently proposed.

For patients with multiple brain metastases, whole brain radiation therapy (WBRT) remains the standard of care. However, the median overall survival is less than 6 months and new approaches need to be developed to improve treatment of these patients.

In this context, the weak control of the disease comes from three main factors: the multiplicity of the brain lesions, the radioresistance of certain histologies and the poor distribution of cytotoxic agents in brain metastases.

The use of radiosensitizing agents is here of great interest. The radiosensitizing agent chosen in this study is AGuIX®. It is a Gadolinium-chelated polysiloxane based nanoparticle developed by NH TherAguix company for its theranostic properties (radiosensitization and diagnosis by multimodal imaging). Preclinical studies have demonstrated the radiosensitizing effect of AGuIX® in vivo in 8 tumor models xenografted in rodents, and particularly in brain tumors.

03

Conditions studied

  • Brain Metastases, Adult
  • Radiotherapy

Browse trials for

Keywords

  • gadolinium nanoparticles
  • AGuIX
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with , from a confirmed solid tumor, eligible for WBRT
  • At least 18 years old
  • Signed after informing the patient
  • (Eastern Cooperative Oncology Group) performance status 0-2
  • Extracranial disease:

    • Complete or partial response or stability under systemic treatment
    • No extracranial disease
    • Or of treatment
  • greater than 6 weeks
  • Effective method for all patient of
  • Affiliated to a social security regimen

Exclusion criteria

Exclusion Criteria:

  • Evidence of with recent large hemorrhage
  • Progressive and threatening extracranial disease under systemic treatment
  • Previous cranial irradiation (except stereotactic irradiation)
  • Known , sensitivity or allergy to gadolinium
  • Known contra-indication for Magnetic Resonance Imaging
  • Renal insufficiency ( ≤ 50 mL/min/1.73m²)
  • Pregnancy or breastfeeding
  • Subject under administrative or judicial control
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    AGuIX® + Whole Brain Radiation Therapy

    Intervention: Drug: AGuIX® + WBRT Other Names: Gadolinium-chelated polysiloxane based nanoparticles 3 intravenous injections at 100mg/kg * D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT) * Fr1: AGuIX® injection before the first radiation session * Fr6: AGuIX® injection before the sixth radiation session 30 Gy in 10 fractions of 3 Gy over 2-3 weeks

    Drug: AGuIX® · Radiation: Whole Brain Radiation Therapy

  • Active comparator
    Whole Brain Radiation Therapy

    Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks

    Radiation: Whole Brain Radiation Therapy

Interventions

  • 3 intravenous injection at 100mg/kg * D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT) * Fr1: AGuIX® injection before the first radiation session * Fr6: AGuIX® injection before the sixth radiation session

    Also known as: Gadolinium-chelated polysiloxane based nanoparticles

  • RadiationWhole Brain Radiation Therapy

    30 Gy in 10 fractions of 3 Gy over 2-3 weeks

    Also known as: WBRT

06

What researchers measure

Primary outcomes

  1. Best objective intracranial response rate - intent-to-treat

    Evaluation of brain metastases response, according to RECIST v1.1 criteria (or modified RECIST) by MRI, with MRI centralized reading

    Time frame: at 6 weeks

  2. Best objective intracranial response rate - intent-to-treat

    Evaluation of brain metastases response, according to RECIST v1.1 criteria (or modified RECIST) by MRI, with MRI centralized reading

    Time frame: at 3 months

Secondary outcomes

  1. Evaluation of the quality of life

    Quality of life test score EORTC QLQ C30

    Time frame: at D0, 6 weeks, 3, 6, 9, 12 months

  2. Evaluation of the quality of life

    Quality of life test score EORTC QLQ BN20

    Time frame: at day 0, 6 weeks, 3, 6, 9, 12 months

  3. Neurocognitive evaluation

    Neurocognitive test (MoCA)

    Time frame: at Day 0, 6 weeks, 3, 6, 9, 12 months

  4. Best objective intracranial response rate - per-protocol

    Evaluation of brain metastases response on per-protocol population, according to RECIST v1.1 criteria (or modified RECIST), by MRI with centralized reading

    Time frame: at 6 weeks and 3 months

  5. Evaluation of the intracranial response rate

    Evaluation of brain metastases response, according to RANO, to RECIST v1.1 criteria, and as the evolution of the sum of longest diameters (for all metastases with a sum of diameters \> 1cm), by MRI, at 6 weeks and 3, 6, 9 and 12 months

    Time frame: for 12 months

  6. Evaluation of individual metastasis response

    Evaluation of individual brain metastasis response, for all metastases with the sum of diameters \> 1cm, by MRI rate

    Time frame: at 6 weeks and 3, 6, 9 and 12 months

  7. Intracranial progression-free survival

    Evaluation of the time between the start of the treatment and the occurence of intracranial progression or neuriologic death

    Time frame: at 12 months

  8. Intracranial progression-free survival, brain survival

    Death related to brain metastases progression

    Time frame: at 12 months

  9. Overall survival

    Death

    Time frame: at 12 months

  10. Change in steroid dependence

    Reporting of daily steroid dose

    Time frame: at 6 weeks and 3, 6, 9 and 12 months

  11. Incidence of adverse events

    Reporting of adverse events by type, frequency and severity for both treatments (WBRT and AGuIX® + WBRT)

    Time frame: at 6 weeks and 3, 6, 9 and 12 months

  12. MRI study of the distribution of the product in brain metastases

    MRI evaluation of contrast enhancement at D0 after AGuIX® injection

    Time frame: Day 0

07

Study locations

14 sites
  • Hospices Civils de Lyon-Hôpital Lyon Sud
    Lyon, France 69495, France
  • Institut Curie Saint Cloud
    Saint-Cloud, France 92210, France
  • Institut Régional du Cancer
    Montpellier, Occitanie 34298, France
  • Institut Claudius Regaud Institut Universitaire du Cancer Toulouse Oncopole Radiothérapie
    Toulouse, Occitanie 31059, France
  • Centre Leon Berard Lyon
    Lyon, Rhones Alpes 69373, France
  • Centre Hospitalier Annecy Genevois
    Annecy, Rhones-Alpes 74374, France
  • Centre Hospitalier Universitaire Grenoble-Alpes
    Grenoble, Rhones-Alpes 38700, France
  • CRLCC - Institut Bergonié
    Bordeaux, 33000, France
  • Crlcc Francois Baclesse
    Caen, 14000, France
  • Centre Georges François Leclerc
    Dijon, 21079, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • La Pitié Salpêtrière - Charles Foix
    Paris, 75651, France
  • Crlcc Paul Strauss
    Strasbourg, 67085, France
  • Institut de Cancérologie de Lorraine ALEXIS VAUTRIN
    Vandœuvre-lès-Nancy, 54519, France
08

References and documents

Publications

  • Le Duc G, Miladi I, Alric C, Mowat P, Brauer-Krisch E, Bouchet A, Khalil E, Billotey C, Janier M, Lux F, Epicier T, Perriat P, Roux S, Tillement O. Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano. 2011 Dec 27;5(12):9566-74. doi: 10.1021/nn202797h. Epub 2011 Nov 9. PubMed 22040385 ↗
  • Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Cremillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Muller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. AGuIX(R) from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2019 Jan;92(1093):20180365. doi: 10.1259/bjr.20180365. Epub 2018 Sep 18. PubMed 30226413 ↗
  • Verry C, Dufort S, Barbier EL, Montigon O, Peoc'h M, Chartier P, Lux F, Balosso J, Tillement O, Sancey L, Le Duc G. MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection. Nanomedicine (Lond). 2016 Sep;11(18):2405-17. doi: 10.2217/nnm-2016-0203. Epub 2016 Aug 16. PubMed 27529506 ↗

Individual participant data

Plan to share: Yes — The provision of patient-level individualized databases (= pseudonymized data) may only be carried out within an appropriate regulatory and contractual framework to ensure compliance with applicable regulations (including the GDPR). Consequently, the data cannot be made freely available; however, you may contact the sponsor (CHUGA) with any requests for access to the data using the following addresses: juristerecherche@chu-grenoble.fr, ArcPromoteur@chu-grenoble.fr, AccueilRecherche@chu-grenoble.fr . This allows to review requests to determine how to respond to them in full compliance with the law, particularly in accordance with regulations regarding the protection of personal data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Availability date: from the moment that the regulatory and contractual framework has been approved by CHUGA. End date: Subject to applicable regulations, the data will be made available for as long as necessary to achieve the scientific objectives.

Access criteria: Anyone who would like to access to study data and/or study documents should be submitted the request to the sponsor via juristerecherche@chu-grenoble.fr, ArcPromoteur@chu-grenoble.fr and/or AccueilRecherche@chu-grenoble.fr. Any data sharing will be subject to the implementation of an appropriate legal and contractual framework, including, where applicable, the execution of a data access agreement, and must fully comply with French regulations on personal data protection (including the French Data Protection Act and applicable CNIL reference methodologies, MR001 for the present clinical trial), the EU General Data Protection Regulation, and the terms of the informed consent provided by participants.

Data sharing details ↗ · www.chu-grenoble.fr

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Sep 2024, 66 months.

Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's 66 months is close to that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Jan 28, 2019
StartActual
Mar 26, 2019
Primary completionActual
Sep 30, 2024
CompletionActual
Jun 18, 2025
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03818386
Collaborators
NH TherAguix SAS
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Mar 26, 2019
Primary completion
Sep 30, 2024
Completion
Jun 18, 2025
Last update
Sep 15, 2026

Study contacts

Camille VERRY, MD
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGuIX

Start the discussion